9. Ramírez Molina VR, Masa JF, de Terreros Caro FJG, et al. The heart in obesity hypoventilation syndrome. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 143–153. 10. Toffart A-C, Pluchart H, Girard N. Cardiovascular effects of innovative therapies in lung cancer. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 154–166. 11. Jutant E-M, Ghigna M-R, Montani D, et al. Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 167–183. 12. Bikdeli B, Rodríguez C, García-Ortega A, et al. Cardiovascular mortality and morbidity in pulmonary embolism. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 184–197. 13. Chong SG, Yanagihara T, Kolb MRJ. The cardiovascular system in idiopathic pulmonary fibrosis. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 198–211. 14. Méndez R, González-Jiménez P, Feced L, et al. Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 212–228. 15. Matera MG, Panettieri Jr RA. β2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 229–237. 16. Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 238–250. 17. Narendra D, Hanania NA. Impact of inhaled corticosteroids in patients with cardiovascular disease. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 251–263. 18. Amati F, Di Pasquale M, Restrepo MI, et al. Cardiovascular side-effects of common antibiotics. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 264–278. 19. Fusco R, Di Paola R, Cuzzocrea S, et al. The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 279–286. 20. Sin DD. Future challanges. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 287–299. 21. Sano H, Hirano T, Koarai A, et al. Case 1. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 300– 304. 22. Revol B, Jullian-Desayes I, Tamisier R, et al. Case 2. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 305–313. 23. Rached S, Athanazio R. Case 3. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 314–317. Disclosures: None declared. https://doi.org/10.1183/2312508X.10005220 xiii